These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11010748)

  • 1. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
    Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
    Prescrire Int; 2000 Jun; 9(47):85-7. PubMed ID: 11010750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
    Prescrire Int; 2000 Jun; 9(47):89-90. PubMed ID: 11010752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antiplatelet agents in ischemic cerebrovascular disease.
    Moussouttas M; Papamitsakis N
    Mt Sinai J Med; 2005 Jan; 72(1):16-22. PubMed ID: 15682258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrinolytics may be cost saving among recent recipients of combined acetylsalicylic acid and clopidogrel who undergo coronary artery bypass graft surgery.
    Ray JG; Hamielec CM
    Can J Cardiol; 2004 Jun; 20(8):829-30. PubMed ID: 15229768
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
    Rothlisberger JM; Ovbiagele B
    J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggrenox: a combination of antiplatelet drugs for stroke prevention.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):11-2. PubMed ID: 10725967
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel: new preparation. An alternative to aspirin.
    Prescrire Int; 1999 Dec; 8(44):163-4. PubMed ID: 11503810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.